{
    "pmcid": "9896449",
    "summary": "The paper titled \"Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity\" presents a comprehensive study on the development of shark-derived nanobodies as potential therapeutics against SARS-CoV-2 and other sarbecoviruses. Here are the key insights related to the design of SARS-CoV-2 nanobody binders:\n\n### Nanobodies and Their Unique Properties:\n1. **Origin and Structure**: Nanobodies are derived from camelids and cartilaginous fishes like sharks. Shark-derived nanobodies, specifically from the new antigen receptor (IgNAR) antibodies, are the smallest known natural nanobodies. They possess a unique structure with a \u03b2-sandwich fold and high variability in their complementarity-determining region 3 (CDR3), allowing a broad paratope repertoire.\n\n2. **Advantages**: Due to their small size and robust stability, nanobodies can access epitopes that are less accessible to conventional antibodies. They also exhibit high rates of somatic mutation, contributing to high-affinity antigen binding.\n\n### Development of SARS-CoV-2 Nanobodies:\n1. **Immunization Strategy**: Nurse sharks were immunized with SARS-CoV-2 spike receptor binding domain (RBD), RBD-ferritin (RFN), and spike-ferritin nanoparticles (SpFN) to elicit a diverse set of VNARs. These immunogens were based on the original SARS-CoV-2 Wuhan-1 virus sequence.\n\n2. **Library Construction and Screening**: Phage-display libraries were constructed from the immunized sharks to capture the VNAR repertoire. These libraries were screened to identify VNARs with high affinity for SARS-CoV-2 RBD and spike proteins.\n\n3. **Characterization of Nanobodies**: Two representative shark antibody variable NAR-Fc chimeras (ShAbs), ShAb01 and ShAb02, were identified. They target two non-overlapping conserved epitopes on the spike RBD. ShAb01 and ShAb02 showed high affinity to all SARS-CoV-2 variants of concern, including Omicron strains, and cross-neutralized SARS-CoV-1 and SARS-CoV-2 pseudoviruses.\n\n### Structural Insights and Epitope Mapping:\n1. **Binding Sites**: ShAb01 binds to a conserved region on the RBD, similar to the CR3022 antibody, while ShAb02 binds to a different conserved region, overlapping with Class-III antibodies like S309. These non-overlapping epitopes allow for potential combination into multi-specific molecules.\n\n2. **Structural Analysis**: The crystal structure of the RBD in complex with ShAb01 and ShAb02 revealed extensive interactions, primarily through the CDR3 loop. This structural information was crucial for designing multi-specific nanobodies with enhanced neutralization capacity.\n\n### Multi-specific Nanobody Design:\n1. **Engineering Multi-specific Molecules**: Using structural insights, multi-specific nanobodies were designed to combine the specificities of ShAb01 and ShAb02. These designs included bispecific and trimeric constructs, which showed improved neutralization potency and breadth against SARS-CoV-2 variants.\n\n2. **Enhanced Neutralization and Binding**: The multi-specific designs demonstrated increased affinity and neutralization potency, particularly against variants like Delta and Omicron. These constructs also maintained ACE2 blocking activity and Fc-mediated effector functions.\n\n### Therapeutic Potential and Broader Implications:\n1. **In Vivo Efficacy**: In a K18-hACE2 transgenic mouse model, ShAb01 and ShAb02 provided significant protection against SARS-CoV-2 challenge, with ShAb01 showing greater protection.\n\n2. **Broad Sarbecovirus Reactivity**: The nanobodies exhibited broad reactivity across sarbecovirus clades, highlighting their potential as pan-sarbecovirus therapeutics.\n\n3. **Future Applications**: The study underscores the potential of shark-derived nanobodies as versatile and potent immunotherapeutics for current and future coronavirus outbreaks. Their small size and stability make them suitable for various delivery methods, including aerosolization.\n\nIn summary, the paper demonstrates the successful development of shark-derived nanobodies with potent neutralizing activity against SARS-CoV-2 and broad reactivity against sarbecoviruses. The structural insights and multi-specific designs provide a promising avenue for next-generation therapeutics capable of addressing emerging viral variants.",
    "title": "Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity"
}